IndraLab
Statements
sparser
"The loss of USP22 causes PD-L1 to be degraded at the post-translational level, which has been shown to reduce carcinogenesis and increase T cell-mediated cell death. xref PD-L1 targeted immunotherapy and CDDP-based chemotherapy were both shown to benefit from USP22 reduction in another research, highlighting the complex and important functions of the USP22-PD-L1 axis in cancer treatment. xref According to a recent research, the tumor-promoting long noncoding RNA (lncRNA) KCNQ1OT1 controls the ubiquitination of PD-L1 and decreases the response of CD8 + T cells via the miR-30a-5p/USP22 pathway."